2.2850
-0.0250
(-1.08%)
As of 12:48:12 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Prashant Kohli | CEO & Director | 599.97k | -- | 1972 |
| Mr. Amresh Kumar Ph.D. | VP of Program Management | 353.5k | -- | 1980 |
| Ms. Carrie D'Andrea | VP of Clinical Operations | 359.05k | -- | 1972 |
| Mr. Robert J. DelAversano CPA | VP of Finance and Principal Financial & Accounting Officer | -- | -- | 1972 |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer | -- | -- | 1962 |
Grace Therapeutics, Inc.
103 Carnegie Center
Suite 300
Princeton, NJ 08540
United States
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Corporate Governance
Grace Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
February 13, 2025 at 1:00 PM UTC
Grace Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
LPCN Lipocine Inc.
3.2523
+2.60%
IRD Opus Genetics, Inc.
0.9566
+2.57%
IOBT IO Biotech, Inc.
1.0092
-5.68%
SCPH scPharmaceuticals Inc.
2.4050
-3.80%
APLT Applied Therapeutics, Inc.
0.4111
-6.78%
MURA Mural Oncology plc
1.2697
-3.81%
LRMR Larimar Therapeutics, Inc.
2.0200
-8.18%
CNTB Connect Biopharma Holdings Limited
0.5777
-8.39%
ATRA Atara Biotherapeutics, Inc.
6.19
+0.98%
FDMT 4D Molecular Therapeutics, Inc.
3.0100
-8.23%